Understanding How mRNA Vaccines Break Down in the Body May One Day Help Fight Cancer

For years, mRNA vaccines have emerged as a groundbreaking advancement in modern medicine, with their potential to revolutionize therapeutics, particularly in cancer treatments. Initially introduced to combat the COVID-19 pandemic, these vaccines are now being explored for their ability to train a patient's immune system to directly target cancer cells.

To enhance the efficacy of mRNA vaccines, researchers from the Olivia Newton-John Cancer Research Institute and the Peter Doherty Institute for Infection and Immunity delved into the distribution, persistence, and degradation of three different COVID-19 vaccines within the human body. By analyzing blood samples from patients, they unveiled unique insights that could pave the way for future cancer therapies and vaccine designs.

According to the senior study author, Yi Ju, lab head at ONJCRI, "mRNA vaccines do not all behave the same way in the bloodstream." The study found contrasting rates at which the mRNA and lipid components declined, as well as varying durations for which sections of the mRNA remained intact. This information could potentially be leveraged to design more efficient vaccines and therapies.

The researchers employed advanced analytical techniques, including polymerase chain reaction (PCR) and liquid chromatography-mass spectrometry (LC-MS), to measure mRNA presence in the blood, assess its integrity, and pinpoint degradation sites. They also evaluated the stability of the lipid-based packaging that encapsulates the mRNA.

The study revealed that most circulating mRNA from the Moderna and Pfizer vaccines had fragmented, with the exact locations of fragmentation within the mRNA molecule identified through follow-up tests. This breakthrough provides a clear understanding of how mRNA vaccines behave in the human body for weeks post-vaccination, without the need for invasive tissue sampling.

The researchers emphasize that defining the behavior of vaccine components in human blood offers a practical window into the performance of mRNA-LNPs, enabling precise comparisons of vaccine components to optimize future designs. These findings hold immense potential for developing more stable vaccines, potentially improving their efficiency, and reducing side effects.

Further studies with small animal models have already demonstrated that increasing mRNA stability or controlling its degradation can lead to enhanced antigen production and better vaccine responses. This knowledge could prove invaluable in the design and evaluation of future, more effective mRNA vaccines and therapies, including those targeted at cancer.